Lexeo Therapeutics (LXEO), a developer of genetic medicines, has filed for an preliminary public providing.
Lexeo didn’t specify phrases in its SEC filing, however indicated in an hooked up submitting payment schedule that it was seeking to elevate $100M, a quantity that’s possible a placeholder and topic to alter.
The corporate hopes to listing its shares on Nasdaq underneath the image LXEO. Bookrunners embody JP Morgan, Leerink Companions, Stifel, RBC Capital Markets and Chardan.
Lexeo’s lead drug candidate, LX2006, is in Section 1/2 testing for Friedrich’s Ataxia cardiomyopathy, with interim knowledge anticipated in mid-2024. The corporate can be conducting Section 1/2 testing on drug candidates for arrhythmogenic cardiomyopathy and Alzheimer’s illness.
Extra on healthcare IPOs
Lexeo Therapeutics (LXEO), a developer of genetic medicines, has filed for an preliminary public providing.
Lexeo didn’t specify phrases in its SEC filing, however indicated in an hooked up submitting payment schedule that it was seeking to elevate $100M, a quantity that’s possible a placeholder and topic to alter.
The corporate hopes to listing its shares on Nasdaq underneath the image LXEO. Bookrunners embody JP Morgan, Leerink Companions, Stifel, RBC Capital Markets and Chardan.
Lexeo’s lead drug candidate, LX2006, is in Section 1/2 testing for Friedrich’s Ataxia cardiomyopathy, with interim knowledge anticipated in mid-2024. The corporate can be conducting Section 1/2 testing on drug candidates for arrhythmogenic cardiomyopathy and Alzheimer’s illness.